Braveheart Bio (NASDAQ:BRVE) Raised to "Strong-Buy" at Jefferies Financial Group

Key Points

• Jefferies Financial Group upgraded Braveheart Bio to “strong buy,” while the broader analyst consensus remains “Buy” with an average price target of $45.25. Recent coverage includes buy or overweight ratings and targets ranging from $40 to $48.
• BRVE shares opened at $25.50, compared with a 12-month trading range of $24.31 to $32.00, leaving the stock below the average analyst target.
• Insiders made substantial purchases, buying 8.75 million shares worth approximately $157.5 million in the last quarter, including two August 7 transactions at $18 per share totaling nearly $69.5 million.

Braveheart Bio (NASDAQ:BRVE - Get Free Report) was upgraded by analysts at Jefferies Financial Group to a "strong-buy" rating in a report issued on Monday, Zacks reports.

A number of other research analysts have also issued reports on the company. Wall Street Zen upgraded Braveheart Bio to a "hold" rating in a research report on Saturday, August 15th. Cantor Fitzgerald started coverage on Braveheart Bio in a report on Monday. They set an "overweight" rating and a $40.00 price target on the stock. TD Cowen started coverage on shares of Braveheart Bio in a research note on Monday. They set a "buy" rating on the stock. The Goldman Sachs Group assumed coverage on shares of Braveheart Bio in a report on Monday. They issued a "buy" rating and a $48.00 price objective for the company. Finally, Stifel Nicolaus began coverage on shares of Braveheart Bio in a research note on Monday. They set a "buy" rating and a $45.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $45.25.

Braveheart Bio Price Performance

Shares of BRVE stock opened at $25.50 on Monday. Braveheart Bio has a 12-month low of $24.31 and a 12-month high of $32.00.

Insider Activity

In other news, Director Erez Chimovits acquired 1,940,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the acquisition, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This represents a 19.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Growth Opportunities F. Forbion bought 1,920,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $34,560,000.00. Following the purchase, the insider directly owned 11,640,546 shares of the company's stock, valued at approximately $209,529,828. This represents a 19.75% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 8,751,942 shares of company stock worth $157,534,956 in the last quarter.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source